LON:REDX Redx Pharma (REDX) Share Price, News & Analysis GBX 15 +3.60 (+31.58%) (As of 04/30/2024) Add Compare Share Share Stock Analysis Stock AnalysisHeadlines About Redx Pharma Stock (LON:REDX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Redx Pharma alerts:Sign Up Key Stats Today's Range 11.42▼ 3350-Day Range 15▼ 1552-Week Range 4▼ 37.90Volume1.42 million shsAverage Volume707,637 shsMarket Capitalization£58.35 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewRedx Pharma Plc engages in drug discovery, pre-clinical development, and licensing activities in the United Kingdom. It discovers and develops small molecule drugs for treating fibrotic disease, cancer, and the emerging area of cancer-associated fibrosis in the areas of unmet medical needs. The company also develops zelasudil (RXC007), a selective rho associated coiled-coil containing protein kinase 2 (ROCK2) inhibitor, which is in Phase 2 clinical trial for the treatment of multiple interstitial lung diseases and cancer-associated fibrosis; RXC008, a potential first-in-class GI-targeted ROCK inhibitor that is in preclinical studies for the treatment of fibrostenotic Crohn's disease; and zamaporvint (RXC004), a porcupine inhibitor that is in Phase 2 clinical trial for targeted therapy of Wnt-ligand dependent cancers. In addition, it is developing RXC009, a potent and selective DDR1 inhibitor, which is in preclinical studies for the treatment of chronic kidney disease; Kirsten rat sarcoma virus (KRAS) inhibitor to target G12D selective and multi-KRAS profiles; RXC006/AZD5055 a porcupine inhibitor, which is in Phase 1 clinical trial for targeting fibrotic diseases, including idiopathic pulmonary fibrosis; JZP815, a pan-rapidly accelerated fibrosarcoma inhibitor that is in Phase 1 clinical trial to overcome resistance mechanisms associated with clinically approved B-RAF selective drugs; and mitogen-activated protein kinase pathway targets for oncology indications. The company has research collaboration agreements with Jazz Pharmaceuticals plc to develop JZP815, as well as discovery and preclinical development of a targeted cancer therapy on the Ras/RAF/MAP kinase pathway; and AstraZeneca plc to develop RXC006/AZD5055, a Porcupine inhibitor for the treatment of fibrotic disease. Redx Pharma Plc was incorporated in 2010 and is based in Macclesfield, the United Kingdom.Read More… Receive REDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Redx Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address REDX Stock News HeadlinesBig Pharma lacks motive to prep for new pandemicsSeptember 11, 2024 | reuters.comBUSINESS LIVE: BT fined over 999 failings; Entain names CEO; UK dividends hit record highJuly 23, 2024 | msn.comURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life-changing for those who are prepared. Why? Because altcoin prices are about to explode.December 18, 2024 | Crypto Swap Profits (Ad)Redx Pharma Plc Shares now trading on JP JenkinsMay 1, 2024 | markets.businessinsider.comRedx boss scooped up shares after revealing London Stock Exchange exitApril 20, 2024 | msn.comRedx Pharma PLC REDXApril 13, 2024 | morningstar.comExodus from Aim leaves chorus of questions in its wakeApril 13, 2024 | thetimes.co.ukLondon markets are broken and closed, says pharma bossApril 10, 2024 | msn.comSee More Headlines REDX Stock Analysis - Frequently Asked Questions How have REDX shares performed this year? Redx Pharma's stock was trading at GBX 22 at the beginning of 2024. Since then, REDX stock has decreased by 31.8% and is now trading at GBX 15. View the best growth stocks for 2024 here. How were Redx Pharma's earnings last quarter? Redx Pharma Plc (LON:REDX) announced its quarterly earnings data on Monday, November, 19th. The company reported ($7.00) earnings per share for the quarter, missing the consensus estimate of ($6.50) by $0.50. How do I buy shares of Redx Pharma? Shares of REDX stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. What other stocks do shareholders of Redx Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Redx Pharma investors own include AutoZone (AZO), Barclays (BARC), Salesforce (CRM), Digital Globe Services (DGS), Intel (INTC), Legal & General Group (LGEN) and OptiBiotix Health (OPTI). Company Calendar Last Earnings11/19/2018Today12/18/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:REDX CUSIPN/A CIKN/A Webredxpharma.com Phone+44-151-7064747FaxN/AEmployees101Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (0.10) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income£-33,160,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-180.80% Return on Assets-43.95% Debt Debt-to-Equity Ratio527.00 Current Ratio1.11 Quick Ratio1.93 Sales & Book Value Annual Sales£4.20 million Price / Sales13.89 Cash FlowGBX 2.87 per share Price / Cash Flow5.23 Book ValueGBX 1 per share Price / Book15.00Miscellaneous Outstanding Shares388,990,000Free FloatN/AMarket Cap£58.35 million OptionableNot Optionable Beta-0.53 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (LON:REDX) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | Sponsored“The Last Retirement Stock You’ll Ever Need”We've just released a critical trade alert about a groundbreaking AI investment opportunity. So, I wanted t...Behind the Markets | SponsoredBitcoin is going to $100,000 … before Inauguration DayMark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Redx Pharma Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Redx Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.